Kineta to Present New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy

On September 25, 2023 Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, reported that it will present a poster on the Company’s anti-CD27 agonist antibody program at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Special Conference on Tumor Immunology and Immunotherapy, to be held on October 1-4, 2023 in Toronto, ON, Canada (Press release, Kineta, SEP 25, 2023, View Source;utm_medium=rss&utm_campaign=kineta-to-present-new-preclinical-data-on-lead-anti-cd27-agonist-antibody-at-aacr-special-conference-on-tumor-immunology-and-immunotherapy [SID1234635385]). Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, will be presenting new preclinical data on the company’s anti-CD27 agonist antibodies in development for the treatment of advanced solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:
Poster Title: CD27 is a new promising T cell co-stimulatory target for cancer immunotherapy
Poster Number: B034
Session: Poster Session B
Session location: Metropolitan Ballroom East
Presenter: Thierry Guillaudeux, Ph.D.
Date / Time: Tuesday, October 3 at 4:45-7:15 P.M.